Cargando…
Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery
Despite the enormity of the societal and health burdens caused by Alzheimer’s disease (AD), there have been no FDA approvals for new therapeutics for AD since 2003. This profound lack of progress in treatment of AD is due to dual problems, both related to the blood–brain barrier (BBB). First, 98% of...
Autor principal: | Pardridge, William M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697739/ https://www.ncbi.nlm.nih.gov/pubmed/33207605 http://dx.doi.org/10.3390/ph13110394 |
Ejemplares similares
-
Advanced Blood–Brain Barrier Drug Delivery
por: Pardridge, William M.
Publicado: (2022) -
Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier
por: Pardridge, William M.
Publicado: (2023) -
Blood-Brain Barrier and Delivery of Protein and Gene Therapeutics to Brain
por: Pardridge, William M.
Publicado: (2020) -
A Historical Review of Brain Drug Delivery
por: Pardridge, William M.
Publicado: (2022) -
Treatment of Parkinson’s disease with biologics that penetrate the blood–brain barrier via receptor-mediated transport
por: Pardridge, William M.
Publicado: (2023)